Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) Gallery

Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Vivo Capital’s Portfolio Company IO Biotech Announces an IPO Gallery

Vivo Capital’s Portfolio Company IO Biotech Announces an IPO

Vivo Capital’s Portfolio Company PatientPop Inc. announced a merger with Kareo Gallery

Vivo Capital’s Portfolio Company PatientPop Inc. announced a merger with Kareo

Vivo Capital’s Portfolio Company Minerva Surgical, Inc. Announces an IPO Gallery

Vivo Capital’s Portfolio Company Minerva Surgical, Inc. Announces an IPO

Vivo’s Portfolio company, Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering Gallery

Vivo’s Portfolio company, Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

Vivo Leads a $32mm Series A Financing in HistoWiz Gallery

Vivo Leads a $32mm Series A Financing in HistoWiz

We are thrilled to reinvest in InBrace, one of our portfolio companies’ $102M, series D financing. Gallery

We are thrilled to reinvest in InBrace, one of our portfolio companies’ $102M, series D financing.

Portfolio Company, Ascendis Pharma, received FDA approval for SKYTROFA® Gallery

Portfolio Company, Ascendis Pharma, received FDA approval for SKYTROFA®

Portfolio Company, Kadmon received FDA approval for REZUROCK Gallery

Portfolio Company, Kadmon received FDA approval for REZUROCK

Vivo is Excited to Announce the IPO of Portfolio Company, Sera Prognostics! Gallery

Vivo is Excited to Announce the IPO of Portfolio Company, Sera Prognostics!

World Health Organization (“WHO”) Authorizes a Vivo Portfolio Company Sinovac Biotech, for Emergency Use Gallery

World Health Organization (“WHO”) Authorizes a Vivo Portfolio Company Sinovac Biotech, for Emergency Use

Vivo Capital invests $50mm in Scientia Vascular Gallery

Vivo Capital invests $50mm in Scientia Vascular

Vivo leads Esco’s $200 million Series A Gallery

Vivo leads Esco’s $200 million Series A

Vivo invests in a Rgenta Gallery

Vivo invests in a Rgenta

Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals Gallery

Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals

Vivo Leads the $25M Aerobiotix, Inc. Growth Equity Deal Gallery

Vivo Leads the $25M Aerobiotix, Inc. Growth Equity Deal

Vivo Invests in Sera Prognostics’ $100 Million Series E Financing Gallery

Vivo Invests in Sera Prognostics’ $100 Million Series E Financing

Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work Gallery

Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work

Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health Gallery

Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health

Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)! Gallery

Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)!

Vivo Portfolio Company, Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China Gallery

Vivo Portfolio Company, Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China

Verona Pharma Raises $200Million in Oversubscribed Private Placement and Subscription Gallery

Verona Pharma Raises $200Million in Oversubscribed Private Placement and Subscription

PatientPop Announces $50M in Series C Funding Gallery

PatientPop Announces $50M in Series C Funding

ALX Oncology Announces Pricing of Initial Public Offering Gallery

ALX Oncology Announces Pricing of Initial Public Offering

Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital Gallery

Preventice Solutions Announces $137 Million Series B Financing Led by Vivo Capital

Genetron Health Announces Pricing of Initial Public Offering Gallery

Genetron Health Announces Pricing of Initial Public Offering

IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Gallery

IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19 Gallery

Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19

Legend Biotech Corporation Announces Pricing of Initial Public Offering Gallery

Legend Biotech Corporation Announces Pricing of Initial Public Offering

RemeGen Completes USD $100 Million Plus in Funding Gallery

RemeGen Completes USD $100 Million Plus in Funding

Gilead to Acquire Forty Seven for $4.9 Billion Gallery

Gilead to Acquire Forty Seven for $4.9 Billion

Passage Bio Announces Pricing of Initial Public Offering Gallery

Passage Bio Announces Pricing of Initial Public Offering

Revolution Medicines Announces Pricing of Initial Public Offering Gallery

Revolution Medicines Announces Pricing of Initial Public Offering

Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors Gallery

Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants Gallery

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

IGM Biosciences Announces Pricing of Initial Public Offering Gallery

IGM Biosciences Announces Pricing of Initial Public Offering

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART Gallery

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

MacuLogix® Raises $38.7 Million in Series D Financing Led by Vivo Capital Gallery

MacuLogix® Raises $38.7 Million in Series D Financing Led by Vivo Capital

Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis Gallery

Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis

Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine Gallery

Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine

Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering Gallery

Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering

Tricida Announces Pricing of Initial Public Offering Gallery

Tricida Announces Pricing of Initial Public Offering